Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS In Brief

This article was originally published in The Gray Sheet

Executive Summary

CMS announces 8.5% improper payment rate for FY 2012. HHS Office of Inspector General expects $6.9 billion in recoveries from audits and investigations. More CMS news.

You may also be interested in...



HHS OIG Expects Almost $4 Billion In Recoveries From First Half Of Fiscal 2013

Its spring 2013 Semiannual Report to Congress says the Office of Inspector General expects recoveries of about $3.8 billion from audits and investigations undertaken in the first half of fiscal year 2013, among other findings.

HHS OIG Targets Medicare DME Costs In 2013 Work Plan

The Office of Inspector General’s fiscal 2013 work plan outlines new projects to monitor costly overpayments for Medicare durable medical equipment and realize additional cost savings in the Medicaid program.

CMS In Brief

Latest news from the Medicare agency.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel